Objective: To evaluate the frequency of and risk factors for epileptic seizures in patients with systemic lupus erythematosus (SLE) in a large cohort series. Methods: One thousand two hundred patients with SLE were analyzed. The type and frequency of risk factors for seizures associated with SLE were studied and compared with two other series reported in the literature. Results: One hundred and forty-two patients had seizures. Seventy-five patients were studied with a mean follow-up of 5 years from the first seizure episode. Fifty-eight (77%) patients had tonic-clonic seizures, 9 (12%) complex partial seizures (PS), 5 (7%) simple partial motor seizures and 3 (4%) secondary tonic-clonic seizures. In 41 (54%) patients, the seizures occurred within the first year of the SLE diagnosis. Recurrence occurred in 40 (53%) patients, and was associated with PS in 14 (35%; p = 0.006) and time of seizures with SLE onset in 5 (12.5%; p = 0.05). Less than one third of the patients had positive antiphospholipid antibodies. A concurrent infection was present in 16 (21%) patients. Conclusions: Epileptic seizures were more common during the first year after SLE diagnosis. Neither infection nor antiphospholipid syndrome was associated with the occurrence of seizures.

1.
Nived O, Sturfelt G, Liang MH, De Pablo P: The ACR nomenclature for CNS lupus revisited. Lupus 2003;12:872–876.
2.
Appenzeller S, Cendes F, Costallat LT: Epileptic seizures in systemic lupus erythematosus. Neurology 2004;63:1808–1812.
3.
Afeltra A, Garzia P, Mitterhofer AP, et al: Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 2003;61:108–110.
4.
Cimaz R, Meroni PL, Shoenfeld Y: Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 2006;15:191–197.
5.
Sachse C, Luthke K, Hartung K, et al: Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. The SLE Study Group. Rheumatol Int 1995;15:23–29.
6.
Sanna G, Bertolaccini ML, Cuadrado MJ, et al: Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003;30:985–992.
7.
Appenzeller S, Cendes F, Costallat LT: Epileptic seizures in systemic lupus erythematosus. Neurology 2004:63:1808–1812.
8.
Mikdashi J, Krumholz A, Handwerger B: Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology 2005;64:2102–2107.
9.
West SG, Emlen W, Wener MH, Kotzin BL: Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995;99:153–163.
10.
Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–1277.
11.
Ainiala H, Hietaharju A, Loukkola J, et al: Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001;45:419–423.
12.
Proposal for revised clinical and electroencephalographic classification of epileptic seizures: from the commission on classification and terminology of the International League against Epilepsy. Epilepsia 1981;22:489–501.
13.
Isenberg D: Comparison of lupus activity indices. Clin Exp Rheumatol 1990;8(suppl 5):37–40.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.